Our findings show a different sensitivity of NSCLC proliferation toward EGCG treatment (A549 > HCC827 > H1975) (Figure 3) which could be attributed in part to the different ability of EGCG to inhibit EGFR signaling. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.